255 related articles for article (PubMed ID: 22419570)
1. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH
Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570
[TBL] [Abstract][Full Text] [Related]
2. Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.
Fuchs KJ; Honders MW; van der Meijden ED; Adriaans AE; van der Lee DI; Pont MJ; Monajemi R; Kielbasa SM; 't Hoen PAC; van Bergen CAM; Falkenburg JHF; Griffioen M
Front Immunol; 2020; 11():659. PubMed ID: 32362897
[TBL] [Abstract][Full Text] [Related]
3. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
[TBL] [Abstract][Full Text] [Related]
4. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
5. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
Front Immunol; 2018; 9():3016. PubMed ID: 30619360
[TBL] [Abstract][Full Text] [Related]
6. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
[TBL] [Abstract][Full Text] [Related]
7. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
[TBL] [Abstract][Full Text] [Related]
8. Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.
Ofran Y; Kim HT; Brusic V; Blake L; Mandrell M; Wu CJ; Sarantopoulos S; Bellucci R; Keskin DB; Soiffer RJ; Antin JH; Ritz J
Clin Cancer Res; 2010 Mar; 16(5):1642-51. PubMed ID: 20160060
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
[TBL] [Abstract][Full Text] [Related]
10. Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2.
Pont MJ; van der Lee DI; van der Meijden ED; van Bergen CA; Kester MG; Honders MW; Vermaat M; Eefting M; Marijt EW; Kielbasa SM; Hoen PA; Falkenburg JH; Griffioen M
Clin Cancer Res; 2016 Aug; 22(16):4185-96. PubMed ID: 26964570
[TBL] [Abstract][Full Text] [Related]
11. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
[TBL] [Abstract][Full Text] [Related]
12. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
13. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
[TBL] [Abstract][Full Text] [Related]
14. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.
Falkenburg JH; Marijt WA; Heemskerk MH; Willemze R
Curr Opin Hematol; 2002 Nov; 9(6):497-502. PubMed ID: 12394171
[TBL] [Abstract][Full Text] [Related]
15. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
16. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity.
Griffioen M; van der Meijden ED; Slager EH; Honders MW; Rutten CE; van Luxemburg-Heijs SA; von dem Borne PA; van Rood JJ; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3837-42. PubMed ID: 18316730
[TBL] [Abstract][Full Text] [Related]
17. Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.
van Bergen CA; van Luxemburg-Heijs SA; de Wreede LC; Eefting M; von dem Borne PA; van Balen P; Heemskerk MH; Mulder A; Claas FH; Navarrete MA; Honders WM; Rutten CE; Veelken H; Jedema I; Halkes CJ; Griffioen M; Falkenburg JH
J Clin Invest; 2017 Feb; 127(2):517-529. PubMed ID: 28067665
[TBL] [Abstract][Full Text] [Related]
18. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.
Warren EH; Fujii N; Akatsuka Y; Chaney CN; Mito JK; Loeb KR; Gooley TA; Brown ML; Koo KK; Rosinski KV; Ogawa S; Matsubara A; Appelbaum FR; Riddell SR
Blood; 2010 May; 115(19):3869-78. PubMed ID: 20071660
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.
Warren EH; Greenberg PD; Riddell SR
Blood; 1998 Mar; 91(6):2197-207. PubMed ID: 9490709
[TBL] [Abstract][Full Text] [Related]
20. Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT.
Olsen KS; Jadi O; Dexheimer S; Bortone DS; Vensko SP; Bennett S; Tang H; Diiorio M; Saran T; Dingfelder D; Zhu Q; Wang Y; Haiman CA; Pooler L; Sheng X; Webb A; Pasquini MC; McCarthy PL; Spellman SR; Weimer E; Hahn T; Sucheston-Campbell L; Armistead PM; Vincent BG
Blood Adv; 2023 May; 7(9):1635-1649. PubMed ID: 36477467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
